THE ULTIMATE GUIDE TO MRTX1133 CLINICAL TRIAL RESULTS

The identification of KRASG12C inhibitors has reignited fascination in targeting RAS proteins. This work describes the invention from the KRASG12D-specific inhibitor MRTX1133 and demonstrates the feasibility of potently and selectively focusing on this oncogenic variant.And clinical trials of mixture therapy with KRAS G12C inhibitors and immune che